← Back to all signals
RESEARCH PAPER ANALYSIS

Cortical gyrification deficits in early-stage Parkinson's disease: the importance of bradykinesia.

MRI analysis of early-stage Parkinson's patients found reduced cortical gyrification in left parahippocampal and lingual gyri and gyrification deficits in right parietal, temporal, and occipital regions that correlate with bradykinesia and functional capacity.

PMID41924695
JournalBrain communications
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

MRI analysis of early-stage Parkinson's patients found reduced cortical gyrification in left parahippocampal and lingual gyri and gyrification deficits in right parietal, temporal, and occipital regions that correlate with bradykinesia and functional capacity.

WHY IT MATTERS

Research significance

Suggests cortical gyrification could serve as a noninvasive biomarker for early diagnosis or progression monitoring linked to motor severity, but offers limited direct therapeutic or mechanistic targets for drug discovery.

ABSTRACT

Source abstract

Timely, accurate diagnosis of Parkinson's disease is still challenging for clinicians. It is therefore crucial to identify novel biomarkers to better characterize the early stages of the disease. Here, we assessed cross-sectional brain structure differences between healthy control (HC) and Parkinson's disease participants. We also explored potential correlations between brain structure and distinctive Parkinson's disease clinical features. We analysed T1-weighted brain images from 381 Parkinson's disease patients, primarily in the early stages, and 139 HC participants obtained from the Parkinson's Progression Markers Initiative (PPMI) database. The image processing protocol included quantification of several brain structure parameters: grey matter volume (GMV), cortical thickness, gyrification index (GI), sulcal depth and surface ratio. Regarding clinical variables, we gathered the Schwab and England score (as a measure of functional capacity), along with four motor symptom scores (bradykinesia, tremor, rigidity and postural instability) derived from the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). We found that the left parahippocampal and lingual gyri showed less gyrification in Parkinson's disease patients compared to HC participants. In Parkinson's disease patients, we also identified GI deficits associated with bradykinesia, the main cardinal motor sign, in right parietal (mainly the supramarginal gyrus), temporal and occipital regions. In addition, higher GI and GMV in the occipital cortex were associated with greater functional capacity in Parkinson's disease. In conclusion, the gyrification deficits observed in early-stage Parkinson's disease patients point to the potential value of cortical folding as a biomarker in Parkinson's disease. Our results indicate that GI deficits are closely associated with bradykinesia and impaired functional capacity, possibly reflecting connectivity issues and/or compensatory mechanisms.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic